Dr. Faraz Khursheed, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 47
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME122905 · LA license MD.207042 -
Interventional Pain Medicine Physician
FL license ME122905
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Neurological Testing Centers of America Inc (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 47
- Services billed
- 1,238
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 490 | 20 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 136 | 18 |
| Established patient office or other outpatient visit, 20-29 minutes | 109 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 25 | 13 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 25 | 14 |
| Ultrasonic guidance for needle placement | 25 | 13 |
| New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Hollywood, FL | 329 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Hollywood, FL | 164 |
| Gabapentin Other prescribers in Hollywood, FL | 163 |
| Amitriptyline Hcl Other prescribers in Hollywood, FL | 114 |
| Tizanidine Hcl Other prescribers in Hollywood, FL | 94 |
| Cyclobenzaprine Hcl Other prescribers in Hollywood, FL | 58 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Hollywood, FL | 48 |
| Xtampza Er (oxycodone myristate) Other prescribers in Hollywood, FL | 38 |
| Tramadol Hcl Other prescribers in Hollywood, FL | 38 |
| Meloxicam Other prescribers in Hollywood, FL | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 75 payments worth $4,270 in total to this clinician.
| Biotronik Nro, Inc. | $3,988 |
|---|---|
| Pfizer Inc. | $108 |
| AbbVie Inc. | $62.67 |
| Globus Medical, Inc. | $40.17 |
| Nalu Medical, Inc. | $26.19 |
| Hyperfine Operations, Inc. | $25.53 |
| Scilex Pharmaceuticals Inc. | $18.88 |
| Food and Beverage | $4,270 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $17,712 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
Sage Therapeutics, LLC - Study to Evaluate SAGE-324 in Participants With Essential Tremors
Sage Therapeutics, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.